First Patient Dosed with MST-0312 in Ph 1 STARLYS Trial
Dr. Elena Garralda MD PhD, Co-Director of the Clinical Research Program and Head of Early Drug Development at Vall d’Hebron Institute of Oncology in Barcelona, Spain, and coordinating Principal Investigator of the STARLYS trial, added, “Published data show that the presence of TLS is associated with significantly improved outcomes for patients. Despite recent therapeutic advances, many patients with solid tumors derive limited benefit from current therapies. MST-0312 is designed to address this unmet need by inducing TLS and reshaping anti-tumor immunity. I look forward to working with the STARLYS investigators to evaluate MST-0312 in the clinic.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome